reference vessel graft diameter diameter !2.5mm and 6mm, were eligible for participation. Patients with cardiogenic shock and acute MI were excluded. Results: 57 patients (27 BMS, 30 DES) were enrolled in 4 centers in 3 European countries. There was no distal embolization in both groups. MACEs rates at 1 and 6 months were resp. 3.7% and 11.1% in BMS group, and 3.3% and 10,0% in DES group. The patients in the DES group, found to be more complex, performed well compared to BMS group, although there was no statistical difference. Conclusions: MACE at 12 months will be presented, as well as lumen loss and angiographic results at 6 months, and OCT followup at 6 months. Background: The Svelte (New Providence, NJ) sirolimus-eluting coronary stent utilizing a bioresorbable amino acid-based (PEA) drug carrier is mounted on a novel Integrated Delivery System (IDS) consisting of a low-compliant balloon with balloon control bands (BCBs) affixed to a 0.014 integrated wire with shapeable tip. The IDS is low-profile and specifically designed for use with the trans-radial approach (TRI), 'slender' PCI and direct stenting. The DIRECT I First-In-Man study (n¼30) reports 2.7% stent volume obstruction (via IVUS) at 6-months with 0% clinically-driven MACE through 24-months. All events and imaging were reviewed and adjudicated by an independent core lab and DSMB. Methods: 159 patients with symptomatic ischemic heart disease due to de novo stenotic lesions in arteries with RVD 2.5mm -3.5mm and lesion length < 20 mm were prospectively randomized (2:1 Svelte IDS : Medtronic Resolute Integrity) at 18 sites in Europe. Clinical and angiographic follow-up was scheduled at 6-months to assess TVF and LL as well as multiple secondary endpoints, with clincial follow-up continuing through 5-years. Stent evaluation post-procedure and at 6-months via OCT was also performed in 30 patients. All events and imaging were reviewed and adjudicated by an independent core lab and DSMB. Results: Study enrolment completed November 2013 (n¼106 Svelte IDS arm, n¼51 Medtronic Resolute Integrity); 6-month data on all available patients is expected May 2014. Procedural, 30-day and 6-month clinical and angiographic data on all patients, along with OCT image analysis (n¼30), will be presented. Comparative data for time and cost savings, including TRI vs. femoral approach, procedure and device time, adjunctive product and contrast use, and radiation exposure, will be reported. Conclusions: A review of the Svelte DES platform and available procedural, 30-day and 6-month angiographic, clinical and OCT outcomes from the study will be reported. These data provide first insights into the safety, efficacy and procedural efficiencies, as well as time and cost savings, of this unique DES IDS system compared with a prospective, matched control group utilizing a conventional DES system.
Higashi-osaka City General Hospital, Higashi-osaka, Osaka
Background: The second generation drug-eluting stents (G2-DES) have been implanted safely at culprit lesions not only of stable angina pectoris but also of acute coronary syndrome. The aim of this study was to angioscopically characterize vascular response after implantation of various G2-DES and to compare healing processes between stable and vulnerable plaques. Methods: Enrolled were consecutive 64 patients who were successfully implanted with various G2-DES. Five patients were withdrawn from further analysis because of death or stroke. Coronary angiography at one year after stenting detected in-stent restenosis in 6 patients, who were excluded from further analysis. Subsequently, coronary angioscopy was performed in 63 lesions (32 vulnerable and 31 stable plaques) of 53 patients, revealing the in-stent appearance of each G2-DES, that is, [1] neointimal stent coverage (NSC, good/poor), [2] presence of thrombus (presence/absence), and [3] presence of yellow plaques (YP, presence/ absence). Results: In-stent thrombus was detected at only 1 vulnerable plaque implanted with BES. As shown in table, in both vulnerable and stable plaques, E-ZES was better covered with neointima than other G2-DES. In stable plaques, no significant differences were found in YP prevalence among G2-DES. In vulnerable plaques, however, prevalence of YP was significantly higher in BES than in another G2-DES.
Conclusions: Vulnerable plaques implanted with BES remained yellowish and thrombogenic even at one year after stenting, suggesting the distinct vascular response after BES implantation at vulnerable plaques.
TCT-601
Comparison of sirolimus-eluting stents with biodegradable polymer versus zotarolimus-eluting stents with durable polymer assessed by optical coherence tomography: The ALSTER-OCT registry Background: Percutaneous coronary interventions (PCI) to small-diameter vessels remain an important challenge because of increased complications. Methods: Between May 2011 and January 2012, 83 patients with very small coronary vessels (reference vessel diameter < 2.25 mm) were submitted to PCI. Biolimus-eluting stent (BES) was deployed at a low pressure with long inflation time.
Results: Two cases of distal edge dissection were observed and one of them needed additional stent implantation. There was no major adverse cardiac event (MACE), including cardiac death, myocardial infarction (MI) and target lesion revascularization (TLR) during the initial hospitalization. The angiographic data is shown in table. Average luminal diameters(ALD) in distal segments markedly increased from baseline to post procedure (1.35AE0.49 mm vs. 1.56AE0.31, p< 0.0001). At 12-months follow-up, the rate of MACE and TLR was 11.1% and 8.1%, respectively. Distal ALD in patients without TLR significantly increased from post procedure to follow-up (1.54AE0.30 mm vs. 1.68AE0.32 mm, p< 0.01).
Conclusions: BES implantation to very small coronary vessels achieved a high clinical success. Vessel diameter distal to stent markedly increased immediately after initial PCI and became larger at 1-year follow-up in case without TLR. Background: Fatigue fracture of coronary stents is a recurring problem that may lead to an array of complications. It is important, both for stent design and selection, to better understand this phenomenon. In this study, the fatigue resistance of three coronary stent designs was qualitatively compared through means of finite element analysis in a patient-specific setting. Methods: Finite element computer simulations were used to virtually deploy and realistically deform three stent designs within a human coronary artery. The three stent models (Element, Boston Scientific; Multi-Link 8, Abbott Vascular; Biomatrix Flex, Biosensors) were generated based on micro-computed tomography scans of device samples. The vessel geometry and deformation was modeled based on biplane fluoroscopy images of a human right coronary artery at diastole and systole. After device deployment and recoil the fatigue safety of the stents was evaluated by imposing a cyclic deformation to the vessel model. The risk of fatigue fracture of different stents or fracture locations within a specific stent is assessed based on these computer simulations, and relative comparisons between stents can be made. Predicted fracture locations and relative fatigue resistances are put into perspective of fatigue fracture data reported in literature. Results: For the investigated patient, the Element was the stent with the highest relative fatigue safety. Relative to the Element stent, the fatigue safety of the MultiLink 8 and Biomatrix Flex stent was 95% and 91%, respectively. Unlike the Element, both the Multi-Link 8 and Biomatrix Flex showed regions of low fatigue safety in the connectors between rings. These results are in close agreement with fatigue fracture data reported in literature. Conclusions: The proposed method for comparing the relative fatigue resistance of coronary devices in a patient-specific setting can be used to optimize device design and selection. Background: Early reports revealed that a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent (named target eluting technology) FIRE-HAWK (MicroPort Medical, Shanghai, China) was safe and effective in 1-year follow-up in a large cohort of patients from the TARGET clinical program. We aimed to investigate the long-term clinical outcomes of this novel stent. Methods: An objective performance criterion (OPC) study was required by the China Food and Drug Administration for new drug-eluting stent. The primary endpoint, target lesion failure (TLF), was defined as the composite of cardiac death, target vessel myocardial infarction (TV-MI), or ischemia-driven target lesion revascularization (iTLR) at 12 months. A patient-level pooled data derived from 
